Jan 23, 2024 · Dr Espen Basmo Ellingsen. University of Oslo . Dr Ellingsen is a Medical Doctor and holds a PhD in cancer immunology from the University of Oslo. Background in translational research from the Institute for Cancer Research at Oslo University Hospital, focusing on therapeutic cancer vaccination, induced immune responses, and their impact on the tumor microenvironment.

Jan 16, 2025 · The University of Virginia Center for Diabetes Technology and Tandem Diabetes Care have entered into a multi-year collaboration agreement to advance research and development in fully automated insulin delivery systems. This partnership will leverage the UVA Center’s groundbreaking work in improving diabetes care through technology-based interventions, along with Tandem’s expertise in ...

Jun 18, 2024 · Mike Holmes, PhD, Chief Scientific Officer at Tessera Therapeutics. Michael joined Tessera in December 2021 as Chief Scientific Officer. Dr Holmes has over 20 years of experience working on the development and clinical translation of different genome editing- and gene therapy-based strategies for the treatment of inherited and acquired diseases.

Aug 28, 2024 · Cliff Brass is an expert in clinical development with special expertise in liver disease and over 25 years of experience in pharma. Most recently Dr Brass was Vice President, Head of Clinical Sciences for Hepatology, Gastroenterology and Transplantation in Global Drug Development at Novartis.

Dec 20, 2024 · Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. Concerns surrounding data security, the complexity of AI systems, and the rigorous regulatory frameworks in this field have caused the pharmaceutical industry to approach these technologies with caution.

Sep 19, 2024 · Based on the positive efficacy and safety data generated in Phase I and II, the plan is to initiate a Phase III programme for mesdopetam. Following successful interactions at the End-of-Phase 2 meeting for mesdopetam with the US Food and Drug Administration (FDA) earlier this year we now look forward to the interactions with European drug regulatory authorities in the autumn for the start of a ...

Feb 13, 2024 · Co-corresponding author Dr David Leib, chair and professor of microbiology and immunology at Geisel, explained: “Despite three decades of trying, the scientific community has been unable to develop an effective vaccine against herpes, and I think the main issue has been that we haven’t fully understood what we need, in terms of antibodies and their specific functions, to protect against ...

Feb 27, 2024 · Residues R418, D422, N430, H433, and Q438 from the LCDR1, LCDR3, and FR2 of the D48 light chain were found to interact polarly with DII. The interaction between HSV-1 gB and D48 was greatly reduced by alanine mutations at these crucial residues.

Aug 6, 2024 · Antibody Drug Conjugates (ADCs) are already deployed as part of the roster of oncology treatments, but here, Mike Ward, Head of Thought Leadership for Life Sciences & Healthcare, Clarivate, looks into their potential to help treat a whole range of other diseases and conditions. He discusses the barriers and enablers that will impact ADCs’ ability to make the shift from oncology to a broader ...

Dec 11, 2024 · Seth Lederman is a physician, scientist and entrepreneur, and a co-founder of Tonix Pharmaceuticals. Prior to Tonix, Dr Lederman founded Targent Pharmaceuticals, which developed late-stage oncology drugs, including levoleucovorin.